Juno Bio started like many health-tech ventures: a straightforward consumer play built around at-home test kits. Mail in a sample, get results, maybe consult a doctor. Simple enough—until it wasn't.
Now the UK-founded vaginal microbiome testing company is making a different bet entirely. It has raised $3.8 million and built its own CLIA-certified sequencing lab in Oakland, California—a facility the company itself positions as the first dedicated entirely to women's health diagnostics. It's a pivot from consumer product to clinical infrastructure operator, and one that suggests the market for precision women's health may demand more than slick branding and a contract lab arrangement.
The funding came from a blend of early-stage backers with genomics or underserved-market theses: Ada Ventures from London, Australia-based Artesian, Entrepreneur First (an early supporter), and Illumina Accelerator. The round wasn't formally designated as a Series A. CB Insights categorizes it as "unattributed VC"—likely a seed extension or bridge, the kind of financing that keeps momentum going without resetting the valuation clock.
Check Warner, co-founding partner at Ada Ventures, backed the move publicly when the funding was announced. The firm has staked out territory in overlooked healthcare categories, and Juno Bio fits that profile neatly.
A Lab of Their Own
The Oakland facility holds high-complexity CLIA certification, a regulatory threshold that allows it to process clinical diagnostic tests without FDA clearance—so long as the tests remain laboratory-developed and comply with state-by-state restrictions. Juno Bio's core offering is a next-generation sequencing test that screens for a wide range of bacteria and fungi, plus four common sexually transmitted infections.
As of the company's recent filings, the test was available as a clinical LDT in 46 U.S. states. In New York, Maryland, Pennsylvania, and Rhode Island—states with tighter laboratory regulations—the company's testing modifications reflect compliance with specific state regulations, offering a wellness-only version that omits STI reporting. According to the company, it has sold more than 20,000 tests to date, though it has not disclosed revenue or unit economics.
Framing the lab as "the first sequencing facility built from the ground up for women's health" is careful positioning. The vaginal microbiome testing category carries baggage. uBiome, the high-profile sequencing startup that once marketed a women's health product called SmartJane, collapsed in 2019 amid federal investigations into billing practices. The category has been rebuilding credibility ever since.
Juno Bio's terms of service, updated as recently as early this year, make the regulatory status explicit: the test is not FDA-cleared or approved. That's standard for LDTs, but it also means the company operates in a zone where clinical claims must be tightly managed.
From Test Kit to Clinical Stack
Hana Janebdar and Dr. Leighton Turner co-founded Juno Bio in 2018. The pair met through Entrepreneur First, the London-based talent-first company builder that specializes in matching technical and commercial co-founders before a business idea fully exists. Juno Bio graduated from Illumina Accelerator, launched its first at-home kit in September 2020, and has since built telehealth and pharmacy integrations to support what it calls a "provider-led care model."
UK Companies House records list Janebdar as a person with significant control for the London-based parent entity, incorporated in mid-2018. The startup straddles two geographies—UK heritage, U.S. clinical operations—a structure common among diagnostics companies navigating divergent regulatory regimes.
The Oakland lab represents a strategic fork. Owning the sequencing stack end-to-end—sample collection, lab processing, clinical interpretation—gives Juno Bio control over turnaround times, quality, and cost structure. It also signals to potential partners (health systems, research institutions, payers) that the company is more than a kit-in-a-box operation.
That matters in a market where competitors are circling. Evvy, another vaginal microbiome testing startup, raised a $14 million Series A in late 2023 and has leaned heavily into consumer education and community-building. The category is still small—Mordor Intelligence pegs the vaginal microbiome testing segment at roughly $160 million in 2025, growing to perhaps $250 million by decade's end—but the clinical validation is accelerating. Peer-reviewed studies linking microbiome dysbiosis to conditions like recurrent UTIs, bacterial vaginosis, and infertility are accumulating, though therapeutic pathways remain murky.
The broader women's health diagnostics market is significantly larger. Grand View Research estimates it at around $20.6 billion in 2024, projected to reach $31.5 billion by 2030. That growth is driven by fertility tracking, prenatal testing, cancer screening, and hormone monitoring—categories with clearer clinical protocols and reimbursement pathways.
Infrastructure as Strategy
Juno Bio is betting that vertical integration will matter more than brand alone. The $3.8 million will fund lab expansion, increase sample throughput, and support broader state-by-state access—though scaling an LDT-based business means navigating a patchwork of regulations that can shift with little warning. The FDA has proposed tightening oversight of LDTs multiple times, most recently in a 2024 rule that the agency later delayed implementing.
For now, Juno Bio operates in a regulatory window: clinical enough to bill insurers (in theory), flexible enough to iterate product without seeking clearance, but exposed if regulators decide to close the gap.
The Oakland lab is, in that sense, both a capacity play and a statement of intent. If precision diagnostics for women's health are going to become standard of care—rather than a niche wellness offering—they'll likely need purpose-built infrastructure. Not every startup can afford to own the lab. Juno Bio is wagering that doing so will prove to be the moat.
Whether that calculus pays off depends on questions the $3.8 million can't answer yet: Will payers reimburse? Will clinicians order? And can a category still shaking off the shadow of uBiome convince the healthcare system it's ready for prime time?
